No abstract available
MeSH terms
-
Adenocarcinoma* / mortality
-
Adenocarcinoma* / therapy
-
Aged
-
Biomarkers, Tumor / analysis
-
Combined Modality Therapy
-
Humans
-
Male
-
Middle Aged
-
Prostate-Specific Antigen / analysis
-
Prostatic Neoplasms* / mortality
-
Prostatic Neoplasms* / therapy
-
Survival Rate
-
Treatment Failure
Substances
-
Biomarkers, Tumor
-
Prostate-Specific Antigen